Automated And Closed Cell Therapy Market Size, Share, Opportunities, And Trends By Workflow (Separation, Expansion, Apheresis, Fill-Finish, Cryopreservation, Others), By Type (Stem Cell Therapy, Non-Stem Cell Therapy), By Scale (Pre-commercial/R&D Scale, Commercial Scale), And By Geography - Forecasts From 2023 To 2028

The automated and closed cell therapy market is estimated to grow at a CAGR of 22.05% during the forecast period.

In closed-system cell therapy, automation is commonly incorporated to streamline and standardize production procedures. Automated systems are capable of carrying out various tasks such as expanding cells, harvesting and separating them, and preparing formulations. Multiple associated benefits with automation in cell therapy along with the growing popularity of regenerative medicines are major growth drivers of the automated and closed cell therapy market. Moreover, the growing prevalence of cancer cases coupled with technological advancements and investments in the field are further expected to boost the automated and closed cell therapy market.

Multiple Associated Benefits

There are various benefits associated with automation which is aiding the automation and closed cell therapy market. Automation in cell therapy provides process standardization, assuring uniform and repeatable cell therapies. Closed systems make it possible to produce more cells in a given time while preserving quality and lowering the chance of an error, which helps with scalability. Closed systems offer a controlled setting for cell therapies, reducing the danger of contamination and guaranteeing the security of cellular products. Automated and closed-cell treatments can increase productivity while lowering labor expenses. Cell treatments are increasingly appealing and available to consumers and healthcare professionals due to their cost-effectiveness.

Increasing Popularity of Regenerative Medicines

Regenerative medicine has grown in popularity recently because it has the potential to transform healthcare by utilizing the body's innate ability to heal itself to repair. The growing popularity of regenerative medicine is a major growth driver of the automated and closed-cell therapy market. Various government measures are supporting the adoption of regenerative medicine. For instance, the NIST Regenerative Medicine program is working closely with FDA to develop global manufacturing and measurement standards. Moreover, NIST Laboratory programs support the regenerative medicine industry by developing new methods for quantitative measurements, providing reference materials, and establishing partnerships to develop measurement solutions.

Growing Prevalence of Cancer

Automated cell therapy has demonstrated remarkable prospects for the treatment of cancer. For example, personalized immunotherapy known as chimeric antigen receptor T-cell (CAR-T) treatment involves altering a patient's T cells so that they can detect and combat cancer cells. The rising cancer cases are therefore expected to bolster the automated and closed cell therapy market. For instance, cancer is the leading death cause with more than 10 million worldwide deaths in 2020 according to the WHO. There were around 18 million new cancer cases worldwide in 2020 as per the WCRF with breast cancer being the most common type accounting for almost 12.5% of overall cases.

Increasing Investments in the Field

The increasing investments in cell therapies to automate the procedure are expected to propel the automated and closed cell therapy market. For instance, Ori Biotech received an investment of €88 million in series B cash to ease the cell therapy manufacturing bottleneck using automation and standardized data collection. Additionally, Cellaries raised $82 million to develop the Cell Shuttle platform which is a modular end-to-end cell therapy factory that leverages automation and quickly turns out a finished product ready for infusion. The platform will require about 80% less cleanroom space than manual production.

Restraints in the Market

A few factors are there which are expected to limit the automated and closed cell therapy market. The essential resources, including clean room facilities, qualified staff, and capacity for process development, may not be present at many healthcare institutions and research organizations. Automated system adoption may be hampered by a lack of infrastructure and competent labor. In the automated cell treatment sector, maintaining product quality and standardizing production procedures are continuing problems that may hinder market growth. The extent of human monitoring and engagement in the manufacturing process is another issue raised by the use of automation in cell therapy that may influence the general public's view and acceptability.

North America is Expected to Grow Significantly

The North American region is anticipated to hold a significant share of the automated and closed cell therapy market. Various factors attributed to such a share are technological advancements, digitalization in healthcare, higher cancer cases, and awareness among healthcare providers and patients. For instance, CDRH established the Digital Health Center of Excellence which seeks to empower digital health stakeholders to advance health care in 2020. Moreover, the new cancer cases in the US were around 1.9 million in 2022 as per the American Cancer Society. Additionally, the presence of major market players such as Miltenyi Biotec, and Cytiva further propels the automated and closed cell therapy market in the region.

Major Market Players

• Lonza is a multinational business that offers sophisticated production and research services to the biopharmaceutical, speciality ingredient, and healthcare industries. Cocoon® platform designed by the company offers cell therapy manufacturing with automated and closed integration.
• Miltenyi Biotec is a global biotechnology company that specializes in providing tools, instruments, and solutions for cellular therapy, cell biology, and immunology research. Their MACS (Magnetic-Activated Cell Sorting) technology is widely used in research laboratories and clinical settings for cell isolation and enrichment.
• Fresenius Kabi is a global healthcare company that focuses on infusion treatment, clinical nutrition, anesthesia, and critical care. Cue® cell processing platform developed by the company offers an automated small cell processing system that addresses critical unmet medical needs.

Key Market Developments

• In May 2023, Cellular Origins launched its configurable robotic platform Constellation™ to enable scalable manufacturing of advanced cell therapies. It combines aseptic fluid handling technologies with advanced automation from the Industry 4.0 revolution.
• In October 2022, to hasten the development of cell therapies in the Asia Pacific region, Thermo Fisher Scientific established a Cell Therapy Collaboration Centre Programme in Singapore. The program seeks to give cell therapy pioneers the tools they need to move quickly from process development to technology transfer for curative cell treatments.
• In October 2022, for simple commercial manufacture of cell treatments, Thermo Fisher Scientific introduced the GibcoTM CTSTM DynaCellectTM Magnetic Separation System. With the help of this technology, production defects are kept to a minimum and the appropriate cells are segregated.

Automated and Closed Cell Therapy Market Scope:

Segmentation:

• By Workflow
  • Separation
  • Expansion
  • Apheresis
  • Fill-Finish
  • Cryopreservation
  • Others
• By Type
  • Stem Cell Therapy
  • Non-Stem Cell Therapy
• By Scale
  • Pre-commercial/R&D Scale
  • Commercial Scale
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others